直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

PTAB Applies Narrow Standards in Granting First Additional Discovery

July 15, 2013

Authored and Edited by Jeffrey C. Totten; Jeffrey A. Berkowitz

In two related inter partes review (IPR) proceedings, both titled Corning Inc. v. DSM IP Assets B.V. (IPR2013-00043 and IPR2013-00046), the Board granted—for the first time—requests for additional discovery. Rather than illustrating loosening of discovery standards, however, these decisions confirm the limited scope of additional discovery available in IPR proceedings.

Applying the factors for additional discovery outlined in Garmin v. Cuozzo (IPR2012-00001), the Board granted DSM’s request for laboratory notebooks, underlying data, and experimental protocols for testing performed by Corning’s expert. The Board found the materials sought by DSM “per se useful” because “Corning has proffered the expert testimony . . . to demonstrate the unpatentability of DSM’s claims.” After finding that the other Garmin factors were met, the Board granted DSM’s request for these materials.

But the Board denied DSM’s other requests for additional discovery. The Board found that DSM had not “narrowly tailored” its request for samples of the prior-art compounds tested by Corning’s expert. In particular, DSM sought all of Corning’s samples, not just those that were difficult to make, and had not asked for specific quantities of each sample. DSM also failed to demonstrate that the request was not unduly burdensome or that it could not obtain the information through other means. Thus, DSM failed to make the showings required by Garmin, and the Board denied discovery of the samples.

The Board also denied DSM’s request for any test results inconsistent with Corning’s invalidity position because this information was “routine discovery” under Section 42.51(b)(1). Corning had already completed routine discovery, so the Board declined to order additional production. The Board also decided Corning did not have to provide a privilege log because DSM had not explained why a log would provide “useful information” and would not be “unduly burdensome.”

These decisions highlight the Board’s narrow reading of what types of additional discovery are “necessary in the interests of justice.” Garmin encourages parties moving for additional discovery to narrowly tailor their requests and to demonstrate that the requested information would be useful. The Corning decisions illustrate that these standards can be met, but continue to be strictly applied.

Tags

United States Patent and Trademark Office (USPTO)

Contacts

Jeffrey C. Totten
Partner
Washington, DC
+1 202 408 4232
Email
Jeffrey A. Berkowitz
Partner
Reston, VA
+1 571 203 2710
Email

Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP